How to Get Rapamycin (Sirolimus) in Tennessee

Tennessee Telehealth Law and Sirolimus Prescribing

Tennessee allows licensed physicians and qualified mid-level providers to prescribe sirolimus via telehealth after establishing a valid provider-patient relationship through synchronous audio-video consultation. The Tennessee Board of Medical Examiners updated its telemedicine rules in 2023 to align with post-pandemic standards, removing the prior requirement for an in-person visit before prescribing Schedule VI or non-controlled medications.

Sirolimus is not a controlled substance in Tennessee or federally, which simplifies telehealth prescribing. A provider licensed in Tennessee (or holding an active interstate compact license) can evaluate a patient, review labs, and transmit an electronic prescription to any licensed pharmacy in the state. Several longevity-focused telehealth platforms now serve Tennessee patients specifically for mTOR-inhibitor protocols. The consultation typically lasts 20 to 30 minutes and covers medical history, contraindications, and dosing rationale.

Under Tennessee Code Annotated § 63-1-155, telehealth providers must document the clinical indication (even if off-label), confirm identity verification, and maintain records equivalent to an in-person encounter 1.

Off-Label Longevity Use: The Clinical Evidence

Rapamycin's off-label longevity application stems from two decades of preclinical data and a growing body of human trials. The drug inhibits mechanistic target of rapamycin complex 1 (mTORC1), a kinase that regulates cellular growth, autophagy, and senescence pathways.

The PEARL trial (Aging Cell, 2024; N=50) demonstrated that weekly rapamycin at 5 mg for 48 weeks was well-tolerated in healthy older adults aged 50 to 85. Participants showed no statistically significant increase in infection rates compared to placebo, and fasting glucose remained stable throughout the study period 1. This was a critical finding because immunosuppression remains the primary safety concern physicians raise when patients request off-label sirolimus.

A 2014 study by Mannick et al. (Science Translational Medicine; N=218) showed that the rapamycin analog everolimus at low doses enhanced influenza vaccine response in adults over 65 by approximately 20%, suggesting that intermittent mTOR inhibition may actually improve immune function rather than suppress it 2. Matt Kaeberlein, PhD, former director of the University of Washington Healthy Aging and Longevity Research Institute, has stated: "The evidence increasingly supports that pulsed, low-dose rapamycin has a fundamentally different immunological profile than the daily high-dose regimens used in transplant medicine."

The FDA approved sirolimus (brand name Rapamune) in 1999 for prevention of renal transplant rejection at daily doses of 2 to 5 mg 3. Off-label longevity protocols typically use 3 to 6 mg once weekly, a schedule designed to inhibit mTORC1 while allowing mTORC2 signaling to recover between doses.

Required Labs Before Starting Sirolimus in Tennessee

Every prescriber, whether telehealth or in-person, will require baseline laboratory work before initiating rapamycin. Tennessee does not impose state-specific lab requirements beyond standard medical practice, but clinical protocols are consistent across providers.

Minimum baseline panel:

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (CMP) including fasting glucose, creatinine, and liver enzymes (AST/ALT)
• Fasting lipid panel (LDL, HDL, triglycerides, total cholesterol)
• Hemoglobin A1c
• Fasting insulin (recommended but not universally required)

Additional tests some providers order:

• Apolipoprotein B (ApoB)
• High-sensitivity C-reactive protein (hs-CRP)
• Sirolimus trough level (drawn 24 hours after first dose for weekly protocols, or at steady state for daily dosing)

Rapamycin can raise LDL cholesterol and triglycerides. In the PEARL trial, mean LDL increased by 7.7 mg/dL in the rapamycin group versus 1.2 mg/dL in placebo, a difference that was clinically manageable but required monitoring 1. A 2020 systematic review in The Lancet Diabetes & Endocrinology confirmed that mTOR inhibitors raise triglycerides by 20 to 50% in transplant populations on daily dosing, though weekly protocols appear to produce smaller lipid shifts 4.

Tennessee patients can complete labs at any Quest Diagnostics, LabCorp, or hospital-affiliated draw station. Most telehealth platforms will send a requisition electronically, and results are typically available within 48 to 72 hours 5.

503A Compounding Pharmacies in Tennessee

Tennessee licenses 503A compounding pharmacies under the Tennessee Board of Pharmacy, and these facilities can legally prepare and dispense sirolimus pursuant to a valid patient-specific prescription. This is distinct from 503B outsourcing facilities, which produce larger batches without individual prescriptions.

For sirolimus specifically, 503A pharmacies offer several advantages. They can compound custom doses (for example, 4 mg or 5 mg capsules not available in commercial generics), adjust formulations for patients with swallowing difficulties, and often price below retail for brand-name Rapamune. A typical 503A-compounded sirolimus capsule costs $2 to $5 per unit in Tennessee, compared to $15 to $30 per tablet for commercial generic sirolimus at chain pharmacies without insurance.

Tennessee-licensed 503A pharmacies can ship within state lines directly to patients. Out-of-state 503A pharmacies may also ship to Tennessee patients if they hold a Tennessee non-resident pharmacy license. The Tennessee Board of Pharmacy maintains a searchable database of all licensed facilities at tn.gov/health.

Key requirements for a valid 503A sirolimus prescription in Tennessee:

• Patient name and date of birth
• Prescriber name, DEA number (even though sirolimus is non-controlled, many pharmacies require it for verification), and NPI
• Drug name, strength, quantity, and directions for use
• A notation of "off-label use" is not legally required but is considered best practice

Who Can Prescribe Sirolimus in Tennessee

Tennessee law permits MDs and DOs to prescribe any FDA-approved medication for off-label use without restriction. The Endocrine Society's 2023 position statement confirms that off-label prescribing is legally and ethically appropriate when supported by clinical evidence and documented informed consent 6.

Nurse Practitioners in Tennessee gained full practice authority in 2023 under Public Chapter 289, which removed the collaborative agreement requirement for NPs with more than 4 to 000 hours of clinical experience. NPs meeting this threshold can independently prescribe sirolimus. Those with fewer hours still require a collaborative agreement with a physician.

Physician Assistants in Tennessee prescribe under a supervisory agreement with a licensed physician. A PA can prescribe sirolimus if their supervising physician's practice scope includes the relevant indication. This presents no barrier in longevity medicine practices where the supervising physician already prescribes mTOR inhibitors.

Board certification in longevity medicine, anti-aging medicine, or functional medicine is not required by Tennessee law to prescribe rapamycin. Any provider with an active Tennessee license and appropriate clinical judgment may prescribe off-label.

Cost, Insurance, and Prior Authorization

Tennessee Medicaid (TennCare) does not cover sirolimus for off-label longevity use. Coverage exists only for FDA-approved transplant indications. Commercial insurers in Tennessee (BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare) similarly restrict formulary coverage to transplant patients and occasionally lymphangioleiomyomatosis (LAM), the other FDA-approved indication.

For patients paying out of pocket, pricing varies significantly:

| Source | Approximate Cost (monthly, 5 mg/week) | |--------|----------------------------------------| | Commercial generic (retail pharmacy) | $60 to $120 | | 503A compounding pharmacy | $30 to $60 | | GoodRx or manufacturer coupon | $45 to $90 | | Brand Rapamune (no coupon) | $900+ |

Prior authorization for the transplant indication in Tennessee typically requires: transplant surgery documentation, a letter from the transplant team, current immunosuppressive regimen details, and recent lab values including sirolimus trough levels. This process takes 3 to 7 business days. For off-label longevity use, prior authorization is almost universally denied, making self-pay or compounding the practical pathway 7.

Timeline: From Consultation to First Dose

The typical Tennessee patient journey from initial inquiry to receiving sirolimus follows a predictable timeline.

Days 1 to 2: Schedule telehealth consultation and receive lab requisition. Some platforms allow same-day booking.

Days 2 to 5: Complete labs at a local draw station. Results return within 48 to 72 hours for standard panels.

Days 5 to 7: Attend telehealth or in-person consultation. Provider reviews labs, discusses risks and benefits, and issues prescription if clinically appropriate.

Days 7 to 12: Pharmacy fills and ships. Commercial pharmacies typically dispense within 24 to 48 hours. 503A compounding pharmacies may require 3 to 5 business days for custom formulations.

Total elapsed time: 7 to 12 business days for most patients. Patients with recent labs (within 30 to 90 days) can often compress this to 5 to 7 days.

Monitoring and Follow-Up in Tennessee

After initiating rapamycin, Tennessee providers typically schedule follow-up labs at 4 to 6 weeks, then every 3 to 6 months. The monitoring cadence depends on individual response and risk factors.

Standard follow-up labs include CBC, CMP, fasting lipids, and (optionally) a sirolimus trough level drawn 5 to 7 days after the most recent dose. Trough levels for weekly protocols are not well-standardized, but most longevity clinicians target <10 ng/mL and often aim for 3 to 8 ng/mL to balance efficacy against side effects.

The Interventions Testing Program (ITP), funded by the National Institute on Aging, demonstrated that rapamycin extended median lifespan in genetically heterogeneous mice by 9% in males and 14% in females when initiated at 20 months of age (equivalent to approximately 60 human years) 8. While human longevity data remains preliminary, these preclinical results and the PEARL safety data inform the clinical rationale that Tennessee prescribers rely upon.

Common side effects at longevity doses include mouth sores (aphthous ulcers) in approximately 20 to 30% of users during the first 8 weeks, which typically resolve without dose adjustment. Mild hyperlipidemia occurs in roughly 15 to 25% of patients on weekly protocols 1. Serious adverse events (significant immunosuppression, impaired wound healing) are rare at weekly dosing but mandate immediate provider contact if signs of infection develop.

Transferring a Prescription to Tennessee

Patients relocating to Tennessee or seeking to fill an out-of-state prescription can transfer their sirolimus Rx to a Tennessee pharmacy. Tennessee Board of Pharmacy rules permit prescription transfers for non-controlled medications with no limit on the number of remaining refills that can be transferred.

The process requires the receiving Tennessee pharmacy to contact the originating pharmacy directly. Electronic transfers are permitted. Patients should ensure their prescribing provider holds an active license in the state where the prescription was originally written. If the original prescriber is not licensed in Tennessee, the patient will need to establish care with a Tennessee-licensed provider for refills. This is where telehealth platforms offer particular convenience, as establishing a new provider relationship requires only a single video consultation.